ArticleBMC cancer2025
Deciphering mismatch repair protein expression variability in gastric cancer: clinical and prognostic implications.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGastric cancer (GC) exhibits diverse molecular characteristics, among which microsatellite instability (MSI) plays a pivotal role in determining treatment responses, particularly to immune checkpoint inhibitors (ICIs). Mismatch repair (MMR) protein immunohistochemical (IHC) staining is a primary screening method for MSI; however, heterogeneity in staining patterns can complicate interpretation.
objectiveThis study aimed to explore the clinicopathological features of GCs with heterogeneous mismatch repair(hMMR) protein expression, specifically (sub)clonal pattern (the coexistence of retained/lost staining in the tumor area), and to assess its association with MSI status.
methodsWe analyzed 1049 cases of gastric adenocarcinoma from the First Affiliated Hospital of Zhejiang University School of Medicine between 2018 and 2024. Heterogeneous staining for MMR proteins was observed in seven cases, characterized by areas of sudden staining loss alongside retained stain. These cases were subjected to tumor microdissection to ascertain MSI status accurately. Also, the association between MSI status and clinicopathological features was investigated in a cohort of 107 selected patients.
resultsOur findings indicated that GCs with hMMR, classified as proficient MMR (pMMR) by IHC, paradoxically exhibited MSI-H status upon microdissection. This discovery underscores the potential for misdiagnosis if intratumoral heterogeneity is overlooked. Furthermore, patients with MSI status displayed distinct clinicopathological features, including older age, distal stomach location, intestinal adenocarcinoma, lower lymphatic metastasis, lower perineural invasion and lower grade of clinical stage. No statistically significant difference in 45-month disease-free survival (DFS) was observed between MSS and MSI cohorts (p = 0.122). The age (p = 0.023, HR:6.017, 95%CI:1.281–28.265) and pTNM stage (p = 0.015, HR:6.632, 95%CI:1.451–30.316) are identified as significant prognostic factors for PFS in patients with GC.
conclusionAccurate diagnosis of MSI status in GC is critical for optimizing therapeutic strategies. We advocate for detailed reporting of MMR protein heterogeneity patterns and quantification of IHC staining in clinical practice to enhance diagnosis precision and enable personalized treatment approaches for GCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.